ब्रेस्ट कैंसर
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
कहाँ जाना है
10 अस्पताल भारत में इस ट्रायल के लिए मरीजों को ले रहे हैं।
रजिस्ट्री समरी (तकनीकी)
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells. HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Ca…
स्पॉन्सर: फाइज़र
ClinicalTrials.gov पर NCT07062965
रजिस्ट्री पर आखिरी अपडेट 19 Oct 2026 · हमने 20 Oct 2026 को पढ़ा